← enGene Holdings Inc. (ENGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
enGene Holdings Inc. (ENGN)
Biological Products, (No Diagnostic Substances) · market cap $135M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2027-01-01
Regulatory
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
enGene Holdings Inc. (ENGN) is a clinical-stage biotech developing EG-70, a gene-therapy-adjacent asset in Phase 2 for superficial (non-muscle-invasive) bladder cancer. The company carries a ~$127M market cap against a precarious financial position: $36.6M cash, roughly 3.8 months of runway, and a most-recent annual net loss of $117M. A Phase 2 data readout on June 30, 2026 was characterized as 'mixed,' introducing meaningful uncertainty around the asset's efficacy profile.
The catalyst path
- 2027-01-01Regulatoryimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| EG-70 (phase 1) | Phase 2 | Superficial Bladder Cancer |
Price & technical context
3-month
+13.6%
6-month
-70.6%
12-month
-69.0%
52-wk range
$1.44–$12.17
vs 50-day MA
+8.6%
vs 200-day MA
-61.1%
Realized vol
184.6%
Max drawdown
-88.2%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ENGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.